Article Information
- Received February 7, 2022
- Revision received August 31, 2022
- Accepted September 17, 2022
- Published online September 23, 2022.
Author Information
- 1Department of Biomedical Engineering, Duke University, Durham, NC, 27708
- 2Neuromodulation Research and Advanced Concepts, Boston Scientific Neuromodulation, Valencia, CA, 91355
- 3Department of Electrical and Computer Engineering, Duke University, Durham, NC, 27708
- 4Department of Neurobiology, Duke University School of Medicine, Durham, NC, 27708
- 5Department of Neurosurgery, Duke University School of Medicine, Durham, NC, 27708
- Correspondence should be addressed to Warren M. Grill at warren.grill{at}duke.edu.
Author contributions
Author contributions: J.E.G., N.T., T.Z., R.E., and W.M.G. designed research; J.E.G. and N.T. performed research; J.E.G. and N.T. analyzed data; J.E.G., N.T., T.Z., R.E., and W.M.G. wrote the paper.
Disclosures
T.Z. and R.E. are employees of Boston Scientific Corporation. J.E.G., N.T., T.Z., and W.M.G. have received royalty payments from Boston Scientific Corporation for licensed I.P. W.M.G received compensation from Boston Scientific as a member of the Neuromodulation Scientific Advisory Board. T.Z. and R.E. own Boston Scientific stock, and R.E. owns stock in NeuroPace.
This work was supported by a grant to Duke University from Boston Scientific Corporation. This work was also supported by the Robert Plonsey Fellowship from the Duke University Department of Biomedical Engineering.
Funding
Boston Scientific Corporation (BSC)
Other Version
- You are viewing the most recent version of this article.
- previous version (September 23, 2022).
Article usage
In this issue
